Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modality-level attribution and redundancy-aware radiomics for MRI-based differentiation of melanoma and NSCLC brain metastases.

Frontiers in oncology·2026
Same author

Explainable incremental-value analysis of apparent diffusion coefficient and arterial spin labeling radiomics for ATRX status prediction in glioblastoma.

Frontiers in oncology·2026
Same author

Limb apraxia in Parkinson's disease and atypical parkinsonian syndromes: a systematic review.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

ASLNet: an explainable deep learning framework for glioma grading and survival prediction.

Frontiers in oncology·2026
Same author

Disentangling verbal learning performance in multiple sclerosis: Dissociating strategy initiation and maintenance.

The Clinical neuropsychologist·2026
Same author

Multimodal artificial intelligence in glioma management: integrating neuroimaging and hematologic biomarkers for precision oncology.

Frontiers in oncology·2026

Related Experiment Video

Updated: Jun 15, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Cognitive dysfunction in multiple sclerosis: the effect of pharmacological interventions.

Epameinondas Lyros1, Lambros Messinis, Sokratis G Papageorgiou

  • 1Department of Neurology, Neuropsychology Section, University of Patras Medical School, 26500, Rion, Patras, Greece. lyrosep@upatras.gr

International Review of Psychiatry (Abingdon, England)
|March 13, 2010
PubMed
Summary

Cognitive dysfunction in multiple sclerosis (MS) significantly impacts quality of life. Pharmacological treatments, including immunomodulatory therapies and acetylcholinesterase inhibitors, show potential benefits for MS cognition, warranting further research.

More Related Videos

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Related Experiment Videos

Last Updated: Jun 15, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Area of Science:

  • Neuroscience
  • Clinical Pharmacology
  • Neurology

Background:

  • Cognitive dysfunction is a prevalent and debilitating symptom in multiple sclerosis (MS).
  • These cognitive deficits significantly impair patients' quality of life and present a major therapeutic challenge.
  • Current understanding of effective pharmacological interventions for MS-related cognitive impairment remains limited.

Purpose of the Study:

  • To review existing research on the cognitive effects of pharmacological treatments in patients with multiple sclerosis (MS).
  • To evaluate the evidence for specific drug classes, such as immunomodulatory treatments and acetylcholinesterase inhibitors, in improving MS cognition.
  • To discuss methodological considerations and future research directions in this field.

Main Methods:

  • Systematic review of studies investigating pharmacological interventions for cognitive dysfunction in multiple sclerosis.
  • Analysis of evidence regarding the efficacy of immunomodulatory treatments, including interferons, on cognitive function.
  • Examination of studies on acetylcholinesterase inhibitors and their impact on cognition in MS patients.

Main Results:

  • Preliminary evidence suggests potential cognitive benefits from immunomodulatory treatments, particularly interferons, in MS.
  • Acetylcholinesterase inhibitors may also offer a beneficial effect on cognition in multiple sclerosis.
  • The current evidence base is limited by the need for larger, multi-center, longitudinal studies.

Conclusions:

  • Pharmacological interventions, including specific immunomodulatory drugs and acetylcholinesterase inhibitors, show promise for improving cognitive function in multiple sclerosis.
  • Further rigorous clinical trials are essential to confirm these findings and establish definitive treatment guidelines.
  • Addressing methodological limitations in current research is crucial for advancing the therapeutic landscape of MS cognitive dysfunction.